Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

NASDAQ on pace to snap a seven-month winning streak as tech drags. Joining me now, markets and data editor Jared Blickery, as well as Michelle Schneider, market gauge. com chief strategist.Jared, I want to start with you. Give us a look at the month here because we saw a lot of damage within tech and that looks like it's going to drag the NASDAQ lower on the month. >> You bet.And let's start with the uh Wi-Fi Interactive. And I'm going to pull up the month to date and this is going to be as of the close Wed ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

Key Takeaways STNE is highlighted as a low P/B stock with a projected 3-5-year EPS growth rate of 30.3%.GLDD stands out with a low P/B and a projected 3-5-year EPS growth rate of 12.0%.KROS qualifies for the value screen with a projected 3-5-year EPS growth rate of 23.6%.When evaluating a company, investors mostly look at a stock’s price-to-earnings (P/E) or price-to-sales (P/S) ratio. While P/E is the ratio of annual earnings to stock price, P/S reflects the amount investors pay for each dollar of revenues ...

Welcome to Young Financ's flagship show, Morning Brief. I'm Julie Hyman. Let's get to the three things you need to know today.First up, it's the final trading day of November. The S&P 500 is on track for its first monthly drop in 6 months, while the Nasdaq may fall for the first time since March. Of course, tech is a big reason why.Super micro computer poised to be the worst performer in the S&P 500 for November. Other losers include Coinbase, Oracle, and Palanteer. Meanwhile, the Chicago Merkantail Exchang ...

BREAKING: Stocks Open Slightly Higher Biotech stocks remain prevalent on the IBD 50 list of winning growth names. While many biotech names are extended. Stoke Therapeutics (STOK) and Mirum Pharmaceuticals (MIRM) are both in or forming bases. And one biotech flashed a sell signal after a breakout failed to progress. Biotech stocks have made tremendous progress off April lows. While many biotech companies are notâ€| Related news ● Take a Trial Today Get instant access to exclusive stock lists, expert market a ...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired Part 2 of a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation. Award-winning CTV News journalist and W5 investigative reporter Jon Woodward provides highlights of Part Two of the series in an article entitled, “‘Something w ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the third quarter ended September 30, 2025 (“Q3 2025”) and provided a corporate update on recent achievements and upcoming milestones. The Company’s unaudited condensed interim consolidated financ ...

In February, I covered Celcuity ( CELC ), stating that the stock price was fundamentally discounting its risk/reward ratio. By that time, Celcuity was a speculative play with deep skepticism around the toxicities associated with oral PI3K inhibitorsI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamenta ...